Objective
We sought to improve ex-vivo diagnostics for drug-induced SCAR by
comparing enzyme-linked immunospot (ELISpot) sensitivities and flow
cytometry-based intracellular cytokine staining (ICS) and cellular
composition of separate samples (PBMC or blister fluid cells (BFC)) from
the same donor.